Combination of chemotherapy with dual antagonists and radiotherapy in the treatment of neoplastic disease.
D000477:Alkylating Agents / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001389:Azirines / Q000627:therapeutic use; D002219:Carbamates / Q000009:adverse effects / Q000627:therapeutic use; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy / Q000628:therapy*; D002800:Cholinesterase Inhibitors; D004273:DNA, Neoplasm / Q000528:radiation effects; D004357:Drug Synergism; D006801:Humans; D010720:Phosphines / Q000627:therapeutic use; D011838:Radiation-Sensitizing Agents; D014520:Urethane / Q000627:therapeutic use
D000477:Alkylating Agents; D000963:Antimetabolites; D000970:Antineoplastic Agents; D001389:Azirines; D002219:Carbamates; D002800:Cholinesterase Inhibitors; D004273:DNA, Neoplasm; D010720:Phosphines; D011838:Radiation-Sensitizing Agents; D014520:Urethane